Wells Fargo raised the firm's price target on Bio-Rad to $310 from $290 and keeps an Equal Weight rating on the shares after meeting with management. The macro environment "remains tough" but Bio-Rad is controlling what it can, the analyst tells investors in a research note. Wells believes the company's EUR 400M loan receivable from Karin Sartorius may not be fully appreciated by investors.
